Application of Translational Science to Clinical Development - Genomic Biomarkers for Pharmaceutical Development - page 21

[66] World Health Organization. < http://www.who.int/mediacentre/factsheets/fs293/en/index.html .> Medicines:
safety of medicines - adverse drug reactions. 2008, accessed January 2013.
[67] Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-
analysis of prospective studies. JAMA 1998;15:1200-5.
[68] Agency for Healthcare Research and Quality. < http: // www.ahrq.gov / qual / aderia / aderia.htm > Reducing and
Preventing Adverse Drug Events to Reduce Hospital Costs. Accessed January 2013.
[69] SEARCH Collaborative Group Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and
statin-induced myopathy - a genomewide study. N Engl J Med 2008;359:789-99.
[70] Abbvie. < http: // www.rxabbvie.com / pdf / humira.pdf > . Humira package insert. Accessed February 2013.
[71] Cutrell AG, Hernandez JE, Fleming JW, Edwards MT, Moore MA, Brothers CH, et al. Updated clinical risk fac-
tor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004;38:2171-2.
[72] Shapiro M, Ward KM, Stern JJ. A near-fatal hypersensitivity reaction to abacavir: case report and literature
review. AIDS Read 2001;11:222-6.
[73] Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B
region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-2.
[74] Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701,
HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet
2002;359:727-32.
[75] Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, PREDICT-1 Study Team. HLA-B*5701
screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79.
[76] Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Study of Hypersensitivity to Abacavir and
Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-b*5701 as a marker
for immunologically conirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis
2008;46:1111-18.
[77] GlaxoSmithKline. < http: // www.viivhealthcare.com / ~ / media / Files / G / GlaxoSmithKline-Plc / pdfs / us_ziagen.pdf >.
Ziagen / abacavir package insert. Accessed January 2013.
[78] Stein SA, Lamos EM, Davis SN. A review of the eficacy and safety of oral antidiabetic drugs. Expert Opin
Drug Saf 2013;12:153-75.
[79] Rubin CJ, Viraswami-Appanna K, Fiedorek FT. Eficacy and safety of muraglitazar: a double-blind, 24-week,
dose-ranging study in patients with type 2 diabetes. Diab Vasc Dis Res 2008;6:205-15.
[80] Geese WJ, Achanzar W, Rubin C, Hariharan N, Cheng P, Tomlinson L, et al. Genetic and gene expression stud-
ies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma
agonists. Pharmacogenet Genomics 2008;18:903-10.